All In Biotech

Drug Trial Radar · NCT06525506

A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease

A Multicenter, Randomized, Double-Masked Phase II Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease

Last checked: Nov 19, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

Sep 4, 2024

Primary completion

Jan 9, 2025

Study completion Sep 22, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-masked phase II study evaluating the efficacy and safety of IBI311 in subjects with inactive or active thyroid eye disease. Approximately 36 subjects meeting the study eligibility criteria will be randomly assigned to the 3-10 mg group, 3-20 mg group, 10 mg group, or 20 mg group on day 1 in a 1:1:2:2 ratio. Dose conversion of the 3-10 mg or 3-20 mg group was performed at week 12. Active and inactive TED was a stratification factor in this study. Active and inactive TED subjects were enrolled in a 1:1 ratio.

Conditions

  • Thyroid Eye Disease

Interventions

  • IBI311 (20 mg)Biological

    Arm 4: 10 mg/kg IBI311 on Day 1, followed by 20 mg/kg IBI311 from week 3 to week 21, Q3W.

  • IBI311 (3-20 mg)Biological

    Arm 2: 3 mg/kg IBI311 from day 1 to week 9, Q3W, followed by 20 mg/kg IBI311 from week 12 to week 21, Q3W.

  • IBI311 (10 mg)Biological

    Arm 3: 10 mg/kg IBI311 from day 1 to week 21, Q3W.

  • IBI311 (3-10mg/kg)Biological

    Arm 1: 3 mg/kg IBI311 from day 1 to week 9, Q3W, followed by 10 mg/kg IBI311 from week 12 to week 21, Q3W.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from Baseline in proptosis in the study eye.Time frame: Week 12
  2. Safety and TolerabilityTime frame: After receiving IBI311 treatment for 48 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Innovent Biologics (Suzhou) Co. Ltd

    Suzhou, Suzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.